New York: Long-term data from a landmark international trial show that about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors live cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Centre investigators and colleagues.
The 10-year follow-up research, published in the New England Journal of Medicine, will bring the phase 3 CheckMate 067 trial to a conclusion.
